Impaired Insulin-mediated Vasorelaxation in a Nonobese Model of Type 2 Diabetes: Role of Endothelin-1

Overview

Journal Can J Physiol Pharmacol

Specialties Pharmacology
Physiology

Date 2008 Jun 3

PMID 18516099

Citations 13

Authors

Mostafa M Elgebaly

Aisha Kelly

Alex K Harris

Hazem Elewa

Vera Portik-Dobos

Pimonrat Ketsawatsomkron

Mario Marrero

Adviye Ergul

Affiliations

Soon will be listed here.

Abstract

Insulin resistance involves decreased phosphorylation of insulin receptor substrate (IRS) proteins and (or) Akt. In the vasculature, modulated Akt phosphorylation may cause impaired vasorelaxation via decreased eNOS activation. Diet-induced insulin resistance enhances endothelin-1(ET-1)-mediated vasoconstriction and prevents vasodilatation to insulin. Presently, we evaluated insulin-mediated vascular relaxation, assessed molecular markers of the insulin signaling pathway, and determined the involvement of ET-1 in response to insulin by using selective ETA- or ETB-receptor blockade in a lean model of type 2 diabetes. Dose-response curves to insulin (0.01-100 ng/mL) were generated with wire myograph using thoracic aorta rings from control Wistar or diabetic Goto-Kakizaki (GK) rats (n=3-11). Maximal relaxation (Rmax) to insulin was significantly impaired and insulin sensitivity was decreased in the GK group. Preincubation with 1 micromol/L BQ-123 or BQ-788 for ETA- and ETB-receptor blockade, respectively, resulted in improved insulin sensitivity. Immunoblotting for native and phosphorylated Akt and IRS-1 revealed a decrease in Akt activation in the GK group. In vivo hyperinsulinemic euglycemic clamp studies showed decreased glucose utilization in GK rats, indicative of insulin resistance. These findings provide evidence that vascular insulin resistance occurs in a nonobese model of diabetes and that both ET receptor subtypes are involved in vascular relaxation to insulin.

Citing Articles

The role of fibrinolysis in the development of prediabetes-associated coronary heart disease: a focus on the plasminogen activator inhibitor -1 and its potential use as a predictive marker in diet-induced prediabetes.

Gumede N, Khathi A Front Nutr. 2023; 10:1256427.

PMID: 38024366 PMC: 10652797. DOI: 10.3389/fnut.2023.1256427.

Plasma Brain Natriuretic Peptide, Endothelin-1, and Matrix Metalloproteinase 9 Expression and Significance in Type 2 Diabetes Mellitus Patients with Ischemic Heart Disease.

Ju C, Ye M, Li F Med Sci Monit. 2015; 21:2094-9.

PMID: 26190179 PMC: 4514296. DOI: 10.12659/MSM.893375.

Cerebrovasculoprotective effects of azilsartan medoxomil in diabetes.

Abdelsaid M, Coucha M, Ergul A Transl Res. 2014; 164(5):424-32.

PMID: 24999268 PMC: 4250409. DOI: 10.1016/j.trsl.2014.06.003.

Targets of vascular protection in acute ischemic stroke differ in type 2 diabetes.

Kelly-Cobbs A, Prakash R, Li W, Pillai B, Hafez S, Coucha M Am J Physiol Heart Circ Physiol. 2013; 304(6):H806-15.

PMID: 23335797 PMC: 3602773. DOI: 10.1152/ajpheart.00720.2012.

Cerebral myogenic reactivity and blood flow in type 2 diabetic rats: role of peroxynitrite in hypoxia-mediated loss of myogenic tone.

Kelly-Cobbs A, Prakash R, Coucha M, Knight R, Li W, Ogbi S J Pharmacol Exp Ther. 2012; 342(2):407-15.

PMID: 22570365 PMC: 3400801. DOI: 10.1124/jpet.111.191296.

References

Balsiger B, Rickenbacher A, Boden P, Biecker E, Tsui J, Dashwood M . Endothelin A-receptor blockade in experimental diabetes improves glucose balance and gastrointestinal function. Clin Sci (Lond). 2002; 103 Suppl 48:430S-433S. DOI: 10.1042/CS103S430S. View

Elgebaly M, Portik-Dobos V, Sachidanandam K, Rychly D, Malcom D, Johnson M . Differential effects of ET(A) and ET(B) receptor antagonism on oxidative stress in type 2 diabetes. Vascul Pharmacol. 2007; 47(2-3):125-30. DOI: 10.1016/j.vph.2007.05.006. View

Standaert M, Sajan M, Miura A, Kanoh Y, Chen H, Farese Jr R . Insulin-induced activation of atypical protein kinase C, but not protein kinase B, is maintained in diabetic (ob/ob and Goto-Kakazaki) liver. Contrasting insulin signaling patterns in liver versus muscle define phenotypes of type 2 diabetic and high.... J Biol Chem. 2004; 279(24):24929-34. DOI: 10.1074/jbc.M402440200. View

Ahlborg G, Shemyakin A, Bohm F, Gonon A, Pernow J . Dual endothelin receptor blockade acutely improves insulin sensitivity in obese patients with insulin resistance and coronary artery disease. Diabetes Care. 2007; 30(3):591-6. DOI: 10.2337/dc06-1978. View

Khan Z, Chakrabarti S . Endothelins in chronic diabetic complications. Can J Physiol Pharmacol. 2003; 81(6):622-34. DOI: 10.1139/y03-053. View

Lteif A, Vaishnava P, Baron A, Mather K . Endothelin limits insulin action in obese/insulin-resistant humans. Diabetes. 2007; 56(3):728-34. DOI: 10.2337/db06-1406. View

Biddinger S, Kahn C . From mice to men: insights into the insulin resistance syndromes. Annu Rev Physiol. 2006; 68:123-58. DOI: 10.1146/annurev.physiol.68.040104.124723. View

Berthiaume N, Carlson C, Rondinone C, Zinker B . Endothelin antagonism improves hepatic insulin sensitivity associated with insulin signaling in Zucker fatty rats. Metabolism. 2005; 54(11):1515-23. DOI: 10.1016/j.metabol.2005.05.019. View

Takahashi K, Ghatei M, Lam H, OHalloran D, Bloom S . Elevated plasma endothelin in patients with diabetes mellitus. Diabetologia. 1990; 33(5):306-10. DOI: 10.1007/BF00403325. View

10.

Janssen U, Vassiliadou A, Riley S, Phillips A, Floege J . The quest for a model of type II diabetes with nephropathy: the Goto Kakizaki rat. J Nephrol. 2004; 17(6):769-73. View

11.

Ferri C, Bellini C, Desideri G, Di Francesco L, Baldoncini R, Santucci A . Plasma endothelin-1 levels in obese hypertensive and normotensive men. Diabetes. 1995; 44(4):431-6. DOI: 10.2337/diab.44.4.431. View

12.

Ergul A, Johansen J, Stromhaug C, Harris A, Hutchinson J, Tawfik A . Vascular dysfunction of venous bypass conduits is mediated by reactive oxygen species in diabetes: role of endothelin-1. J Pharmacol Exp Ther. 2004; 313(1):70-7. DOI: 10.1124/jpet.104.078105. View

13.

Lundberg J, Alvestrand A, Ahlborg G . Exogenous endothelin-1 causes peripheral insulin resistance in healthy humans. Acta Physiol Scand. 1997; 161(2):211-20. DOI: 10.1046/j.1365-201X.1997.00212.x. View

14.

Miller A, Tulbert C, Puskar M, Busija D . Enhanced endothelin activity prevents vasodilation to insulin in insulin resistance. Hypertension. 2002; 40(1):78-82. DOI: 10.1161/01.hyp.0000022806.87281.62. View

15.

White M . Insulin signaling in health and disease. Science. 2003; 302(5651):1710-1. DOI: 10.1126/science.1092952. View

16.

Battistini B, Berthiaume N, Kelland N, Webb D, Kohan D . Profile of past and current clinical trials involving endothelin receptor antagonists: the novel "-sentan" class of drug. Exp Biol Med (Maywood). 2006; 231(6):653-95. View

17.

Hotamisligil G . Inflammation and metabolic disorders. Nature. 2006; 444(7121):860-7. DOI: 10.1038/nature05485. View

18.

Wilkes J, Hevener A, Olefsky J . Chronic endothelin-1 treatment leads to insulin resistance in vivo. Diabetes. 2003; 52(8):1904-9. DOI: 10.2337/diabetes.52.8.1904. View

19.

Saltiel A, Kahn C . Insulin signalling and the regulation of glucose and lipid metabolism. Nature. 2001; 414(6865):799-806. DOI: 10.1038/414799a. View

20.

Haak T, Jungmann E, Felber A, Hillmann U, Usadel K . Increased plasma levels of endothelin in diabetic patients with hypertension. Am J Hypertens. 1992; 5(3):161-6. DOI: 10.1093/ajh/5.3.161. View